FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:832-838 September 28, 1995 Number 13 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Myoblast transfer has been proposed as a technique to replace dystrophin, the skeletal-muscle protein that is deficient in Duchenne's muscular dystrophy. Donor myoblasts injected into muscles of affected patients can fuse with host muscle fibers, thus contributing their nuclei, which are potentially capable of replacing deficient gene products. Previous controlled trials involving a single transfer of myoblasts have been unsuccessful.

Methods We injected donor muscle cells once a month for six months to the biceps brachii muscles of one arm of each of 12 boys with Duchenne's muscular dystrophy. The opposite arms served as sham-injected controls. In each procedure 110 million cells donated by fathers or brothers were transferred. The patients were randomly assigned to receive either cyclosporine or placebo. Strength was measured by quantitative isometric muscle testing. Six months after the final myoblast transfer, the presence of dystrophin was assessed with the use of peptide antibodies specific to the deleted exons of the dystrophin gene.

Results There was no significant difference in muscle strength between arms injected with myoblasts and sham-injected arms. In one patient, 10.3 percent of muscle fibers expressed donor-derived dystrophin after myoblast transfer. Three other patients also had a low level of donor dystrophin (<1 percent); eight had none.

Conclusions Myoblasts transferred once a month for six months failed to improve strength in patients with Duchenne's muscular dystrophy. The value of exon-specific peptide antibodies in the interpretation of myoblast-transfer results was demonstrated in a patient with Duchenne's muscular dystrophy who had a high percentage of donor-derived dystrophin. Specific variables affecting the efficiency of myoblast transfer need to be identified in order to improve upon this technique.

Source Information

From the Departments of Neurology (J.R.M., J.T.K., A.A.A., W.K., L.S., T.W.P., Z.S., S.B., P.E.M., R.R., A.H.M.B.), Pathology (J.R.M., T.W.P., R.S., L.L.), Medical Biochemistry (A.H.M.B.), Statistics (H.N.), and Molecular Genetics (P.E.M., A.H.M.B.), Ohio State University, Columbus; and the North East Wales Institute, Research Division, Deeside, Clwyd, United Kingdom (G.E.M.).

Address reprint requests to Dr. Mendell at the Department of Neurology, Rm. 463, Means Hall, Ohio State University, 1654 Upham Dr., Columbus, OH 43210.

Full Text of this Article

This article has been cited by other articles:

• Chang, H., Yoshimoto, M., Umeda, K., Iwasa, T., Mizuno, Y., Fukada, S.-i., Yamamoto, H., Motohashi, N., Miyagoe-Suzuki, Y., Takeda, S., Heike, T., Nakahata, T. (2009). Generation of transplantable, functional satellite-like cells from mouse embryonic stem cells. FASEB J. 23: 1907-1919 [Abstract] [Full Text]  
• Li, Z., Lee, A., Huang, M., Chun, H., Chung, J., Chu, P., Hoyt, G., Yang, P., Rosenberg, J., Robbins, R. C., Wu, J. C. (2009). Imaging survival and function of transplanted cardiac resident stem cells.. J Am Coll Cardiol 53: 1229-1240 [Abstract] [Full Text]  
• Urish, K. L., Vella, J. B., Okada, M., Deasy, B. M., Tobita, K., Keller, B. B., Cao, B., Piganelli, J. D., Huard, J. (2009). Antioxidant Levels Represent a Major Determinant in the Regenerative Capacity of Muscle Stem Cells. Mol. Biol. Cell 20: 509-520 [Abstract] [Full Text]  
• Wallace, G. Q., Lapidos, K. A., Kenik, J. S., McNally, E. M. (2008). Long-Term Survival of Transplanted Stem Cells in Immunocompetent Mice with Muscular Dystrophy. Am. J. Pathol. 173: 792-802 [Abstract] [Full Text]  
• Kimura, E., Han, J. J., Li, S., Fall, B., Ra, J., Haraguchi, M., Tapscott, S. J., Chamberlain, J. S. (2008). Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Hum Mol Genet 17: 2507-2517 [Abstract] [Full Text]  
• Cui, C.-H., Uyama, T., Miyado, K., Terai, M., Kyo, S., Kiyono, T., Umezawa, A. (2007). Menstrual Blood-derived Cells Confer Human Dystrophin Expression in the Murine Model of Duchenne Muscular Dystrophy via Cell Fusion and Myogenic Transdifferentiation. Mol. Biol. Cell 18: 1586-1594 [Abstract] [Full Text]  
• Karol, L. A. (2007). Scoliosis in Patients with Duchenne Muscular Dystrophy. JBJS 89: 155-162 [Full Text]  
• Lovering, R. M, Porter, N. C, Bloch, R. J (2005). The Muscular Dystrophies: From Genes to Therapies. ptjournal 85: 1372-1388 [Abstract] [Full Text]  
• Chakkalakal, J. V., Thompson, J., Parks, R. J., Jasmin, B. J. (2005). Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J. 19: 880-891 [Abstract] [Full Text]  
• Bachrach, E., Li, S., Perez, A. L., Schienda, J., Liadaki, K., Volinski, J., Flint, A., Chamberlain, J., Kunkel, L. M. (2004). Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proc. Natl. Acad. Sci. USA 101: 3581-3586 [Abstract] [Full Text]  
• Wiendl, H., Mitsdoerffer, M., Hofmeister, V., Wischhusen, J., Weiss, E. H., Dichgans, J., Lochmuller, H., Hohlfeld, R., Melms, A., Weller, M. (2003). The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain 126: 176-185 [Abstract] [Full Text]  
• Jankowski, R. J., Deasy, B. M., Cao, B., Gates, C., Huard, J. (2002). The role of CD34 expression and cellular fusion in the regeneration capacity of myogenic progenitor cells. J. Cell Sci. 115: 4361-4374 [Abstract] [Full Text]  
• Chamberlain, J. S. (2002). Gene therapy of muscular dystrophy. Hum Mol Genet 11: 2355-2362 [Abstract] [Full Text]  
• Qu-Petersen, Z., Deasy, B., Jankowski, R., Ikezawa, M., Cummins, J., Pruchnic, R., Mytinger, J., Cao, B., Gates, C., Wernig, A., Huard, J. (2002). Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. JCB 157: 851-864 [Abstract] [Full Text]  
• Sussman, M. (2002). Duchenne Muscular Dystrophy. J Am Acad Orthop Surg 10: 138-151 [Abstract] [Full Text]  
• Isner, J. M., Vale, P. R., Symes, J. F., Losordo, D. W. (2001). Assessment of Risks Associated With Cardiovascular Gene Therapy in Human Subjects. Circ. Res. 89: 389-400 [Abstract] [Full Text]  
• Lee, J. Y., Qu-Petersen, Z., Cao, B., Kimura, S., Jankowski, R., Cummins, J., Usas, A., Gates, C., Robbins, P., Wernig, A., Huard, J. (2000). Clonal Isolation of Muscle-Derived Cells Capable of Enhancing Muscle Regeneration and Bone Healing. JCB 150: 1085-1100 [Abstract] [Full Text]  
• Chapdelaine, P., Moisset, P.-A., Campeau, P., Asselin, I., Vilquin, J.-T., Tremblay, J. P. (2000). Functional EGFP-dystrophin fusion proteins for gene therapy vector development. Protein Eng Des Sel 13: 611-615 [Abstract] [Full Text]  
• Beauchamp, J. R., Morgan, J. E., Pagel, C. N., Partridge, T. A. (1999). Dynamics of Myoblast Transplantation Reveal a Discrete Minority of Precursors with Stem Cell-like Properties as the Myogenic Source. JCB 144: 1113-1122 [Abstract] [Full Text]  
• Tuszynski, M. H. (1998). Review : Gene Therapy: Applications to the Neurosciences and to Neurological Disease. Neuroscientist 4: 398-407 [Abstract]  
• Qu, Z., Balkir, L., van Deutekom, J. C.T., Robbins, P. D., Pruchnic, R., Huard, J. (1998). Development of Approaches to Improve Cell Survival in Myoblast Transfer Therapy. JCB 142: 1257-1267 [Abstract] [Full Text]  
• Joynt, R. J. (1996). Neurology. JAMA 275: 1826-1827 [Abstract]  
• Blau, H. M., Springer, M. L. (1995). Muscle-Mediated Gene Therapy. NEJM 333: 1554-1556 [Full Text]  
• Leiden, J. M. (1995). Gene Therapy -- Promise, Pitfalls, and Prognosis. NEJM 333: 871-873 [Full Text]  
• Whitney, M. L., Otto, K. G., Blau, C. A., Reinecke, H., Murry, C. E. (2001). Control of Myoblast Proliferation with a Synthetic Ligand. J. Biol. Chem. 276: 41191-41196 [Abstract] [Full Text]